Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03534687 · ClinicalTrials.gov registry record · NA

Exercise and the Receptor for Advanced Glycation End Products (RAGE)

A NA study of Diabetes Mellitus, Type 2, sponsored by University of Michigan.

Completed
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT03534687 is a NA study of Diabetes Mellitus, Type 2 that has completed, run by University of Michigan. The registered enrollment target is 50 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03534687, a NA study of Diabetes Mellitus, Type 2, has completed, sponsored by University of Michigan.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

This study examines the effects of 12-weeks of aerobic exercise training on the mechanisms driving RAGE-mediated inflammation in type 2 diabetic humans.

Conditions Studied

Interventions

  • BEHAVIORAL Aerobic Exercise

Study Locations (1)

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2018-12-20
Est. Completion 2023-05-08
Phase NA

Sponsor

University of Michigan

1,327 total trials

What the Registry Record Tells You About NCT03534687

The ClinicalTrials.gov registry entry for NCT03534687 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Aerobic Exercise is the first listed.

NCT03534687 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT03534687 about?

NCT03534687 is a clinical study titled "Exercise and the Receptor for Advanced Glycation End Products (RAGE)". This study examines the effects of 12-weeks of aerobic exercise training on the mechanisms driving RAGE-mediated inflammation in type 2 diabetic humans.

What is the current status of trial NCT03534687?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2018-12-20. Estimated completion is 2023-05-08.

What conditions does trial NCT03534687 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.

What interventions are being tested in trial NCT03534687?

The interventions under investigation include: Aerobic Exercise (BEHAVIORAL).

Who is sponsoring clinical trial NCT03534687?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03534687 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.